13F Holdings
中文EN

GOSS Gossamer Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1728117 · Fiscal year ends 12/31

Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-58.0%
TTM net income YoY-71.6%
TTM EPS YoY-221.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-361.9%
Net margin-344.8%
FCF margin-383.7%
EBITDA margin-361.1%

Returns

ROE-783.4%
ROA-45.2%
ROIC (approx.)—
Asset turnover0.13x

Leverage & solvency

Liabilities / assets119.1%
Debt / equity—
Current ratio4.40x
Interest coverage-13.28x

Cash quality & payout

Operating cash flow / net income1.11x
Accruals ratio5.1%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$38.43M$9.24M$16.95M$13.80M$13.29M$11.49M$9.89M$9.38M
R&D expense$18.83M$26.41M$43.08M$48.94M$45.54M$41.58M$38.04M$36.11M
SG&A expense$9.64M$8.90M$18.75M$10.90M$9.39M$8.68M$8.66M$9.39M
Operating income$7.20M-$26.07M-$44.87M-$46.04M-$49.11M-$38.77M-$36.81M-$36.13M
Interest expense$2.46M$2.71M$2.75M$2.75M$2.75M$2.74M$2.75M$2.74M
Pretax income———-$47.33M-$48.22M-$38.27M—-$35.44M
Income tax———-$88,000$0$0—-$2.41M
Net income-$48.07M$16.90M-$46.66M-$47.24M-$48.22M-$38.27M-$36.64M-$33.03M
EBITDA$7.20M-$26.07M-$44.86M-$46.03M-$49.11M-$38.76M-$36.80M-$36.02M
EPS (basic)-7.360.05-0.20—-16.92-0.17-0.16—
EPS (diluted)-7.36-0.08-0.20—-16.92-0.17-0.16—
Weighted avg. shares (diluted)6.53M328.78M234.14M—2.85M227.28M226.82M—
Balance sheet
Cash & equivalents$51.19M$41.15M$41.03M$37.73M$8.93M$26.31M$29.02M$46.07M
Short-term investments$0$15.88M$58.19M$99.20M$171.29M$186.61M$228.91M$248.44M
Receivables$0$6.11M$9.25M$12.23M$9.24M$7.58M$6.58M$5.34M
Current assets$60.43M$72.72M$124.54M$167.64M$203.99M$235.90M$275.48M$309.89M
PP&E, net$51,000$55,000$59,000$64,000$70,000$76,000$29,000$10,000
Total assets$64.34M$76.87M$128.90M$172.25M$208.82M$240.93M$280.59M$315.29M
Current liabilities$99.94M$137.78M$56.51M$63.44M$62.12M$53.59M$48.22M$45.01M
Short-term debt———————$0
Long-term debt———————$0
Total debt———————$0
Total liabilities$187.13M$170.90M$290.38M$295.01M$291.15M$287.03M$286.84M$285.80M
Shareholders' equity-$122.80M-$94.03M-$161.48M-$122.76M-$82.33M-$46.11M-$6.25M$29.49M
Net debt———————-$46.07M
Shares outstanding6.12M488.85M234.70M2.92M231.31M227.32M227.22M226.60M
Cash flow statement
Operating cash flow-$29.58M-$39.42M-$38.72M-$48.31M-$36.17M-$47.06M-$39.72M-$35.48M
Capital expenditure$0$0$0$0$0$53,000$26,000$0
Free cash flow-$29.58M-$39.42M-$38.72M-$48.31M-$36.17M-$47.11M-$39.75M-$35.48M
Investing cash flow$15.90M$42.70M$41.61M$73.16M$17.01M$44.13M$22.06M$53.22M
Financing cash flow$23.72M-$3.14M$512,000$3.96M$1.87M$94,000$504,000$0
Depreciation & amortization$4,000$4,000$5,000$6,000$6,000$6,000$6,000$108,000
Stock-based compensation$3.79M$2.46M$6.30M$2.90M$2.67M$2.59M$2.40M$4.96M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.